Whoop Unveils Comprehensive Women’s Health Panel and Enhanced Menstrual Cycle Tracking

Fitness wearable innovator Whoop is significantly expanding its focus on women’s health, announcing the launch of a new dedicated panel through its Whoop Labs blood testing service. This initiative is complemented by a substantial update to its accompanying application, introducing a sophisticated feature designed to surface detailed information and predictions related to hormonal changes experienced throughout menstrual cycles. These developments underscore a growing industry trend towards addressing the historically underserved health needs of women within the wearable technology sector.

The newly introduced women’s health panel, a key offering from Whoop Labs, is meticulously designed to provide profound insights into various facets of female physiology. It comprises an extensive array of 11 critical blood biomarkers, each selected for its relevance to cycle regulation, hormonal transitions, and broader systemic health. These biomarkers include Anti-Müllerian Hormone (AMH), Progesterone, Prolactin, Thyroid Peroxidase Antibodies (TPOAb), Free T4, Free T3, Leptin, Vitamin B12 (Cobalamin), Folate, Magnesium, and Phosphate (measured as Phosphorus).

Each biomarker plays a distinct role in understanding a woman’s health landscape. Anti-Müllerian Hormone (AMH) is a crucial indicator of ovarian reserve, offering insights into fertility potential and the progression towards perimenopause. Progesterone, a steroid hormone, is vital for regulating the menstrual cycle, supporting the luteal phase, and preparing the body for potential pregnancy, with fluctuations impacting mood, sleep, and energy. Prolactin, primarily known for its role in milk production, can also influence menstrual regularity and fertility when levels are imbalanced.

The inclusion of Thyroid Peroxidase Antibodies (TPOAb), Free T4, and Free T3 highlights Whoop’s commitment to assessing thyroid function, a common area of concern for women. TPOAb indicates the presence of an autoimmune thyroid condition, such as Hashimoto’s thyroiditis, which can significantly affect metabolism, energy levels, and reproductive health. Free T4 and Free T3 are active thyroid hormones that regulate metabolism, energy, and body temperature, providing direct measures of thyroid gland activity. Understanding these markers can reveal crucial information about metabolic health and overall vitality.

Beyond hormonal and thyroid indicators, the panel also delves into metabolic and nutritional sufficiency. Leptin, a hormone produced by fat cells, plays a critical role in regulating appetite, energy balance, and metabolism, often interacting with other reproductive hormones. Deficiencies in essential nutrients like Vitamin B12 (Cobalamin) and Folate are common and can impact energy production, nerve function, and red blood cell formation, all of which are particularly important for women’s health, including during pregnancy planning. Magnesium and Phosphate (Phosphorus) are vital minerals contributing to bone health, muscle function, nerve transmission, and energy production, and their levels can reflect dietary intake and metabolic processes, impacting bone metabolic resilience.

Whoop asserts that when data from these blood biomarkers is synergistically paired with its existing comprehensive data on a user’s activity levels, sleep patterns, and recovery metrics, it creates a powerful, integrated view of health. This holistic approach is designed to help users gain a deeper understanding of complex physiological states such as perimenopause, assess their thyroid function, evaluate nutrient sufficiency, and gauge their bone metabolic resilience. The combination of internal physiological markers with external lifestyle data aims to provide actionable insights for optimizing overall well-being.

The new women’s health panel is slated to become available for purchase by Whoop users starting next month. The anticipated demand for this service is significant, building upon the substantial interest generated when Whoop initially launched its blood testing service in September 2025. At that time, the company reported an impressive waitlist exceeding 350,000 individuals, underscoring a strong market appetite for personalized health insights derived from biomarker analysis.

Concurrently with the new blood panel, Whoop is rolling out a sophisticated "Hormonal Symptom Insights and Predictions" feature within its application. This innovative tool leverages a user’s historical data to construct a personalized model of hormonal changes occurring throughout their menstrual cycles. Utilizing this dynamic model, the app can offer accurate predictions for possible date windows of a user’s next period, provide detailed insights into individual cycle lengths, period durations, and identify any irregularities that may arise. Furthermore, it tracks and details individual symptom patterns, allowing users to understand how their bodies respond at different phases of their cycle.

A key strength of this new app feature lies in its ability to seamlessly integrate with the Whoop Labs blood test results. This integration enables the platform to categorize biomarker results into intuitive ‘optimal,’ ‘sufficient,’ or ‘out of range’ classifications. By cross-referencing physiological data from blood tests with the day-to-day experience captured by the app’s symptom tracking, Whoop aims to provide users with a truly comprehensive and actionable understanding of their hormonal health. For instance, a user experiencing persistent fatigue (tracked via the app) might find their Free T3 levels categorized as ‘out of range,’ prompting a more informed discussion with a healthcare provider.

To provide a robust scientific foundation for these new features, Whoop has also published a new menstrual cycle white paper. This document delves into the intricate modeling and research underpinning the advanced insights and predictions offered by the company’s latest women’s health innovations, offering transparency and scientific backing to its user base.

Whoop’s strategic expansion into women’s health is reflective of a broader, transformative trend within the fitness wearable industry. For too long, women’s unique physiological needs have been an underserved segment of the health and fitness technology market. However, a noticeable shift is occurring, with companies increasingly recognizing and responding to the demand for more tailored and nuanced health solutions for women. This month alone, smart ring manufacturer Oura, a prominent competitor, also launched a proprietary AI model specifically focused on women’s health, alongside an AI-powered chatbot designed to provide personalized insights and answer health-related questions. This parallel development highlights a collective industry effort to innovate in this critical area.

Whoop’s internal data strongly validates this market direction. The company reported a remarkable 150% increase in women using its products over the past year, establishing this demographic as its fastest-growing user segment. Furthermore, women users demonstrate a significantly higher engagement rate with the Whoop AI feature, interacting with it 30% more than other user groups. These statistics not only underscore the substantial demand for women-specific health tools but also indicate a strong receptiveness to advanced analytical and personalized insights.

This observation is consistent with market trends reported by other industry leaders. In October 2025, Dorothy Kilroy, Oura’s chief commercial officer, shared with TechCrunch that the company’s fastest-growing user base at that time consisted of women in their twenties. Such data points from multiple leading wearable companies collectively paint a clear picture: there is a significant, growing, and engaged female demographic actively seeking sophisticated technological solutions to better understand and manage their health, particularly concerning hormonal and reproductive well-being. Whoop’s latest offerings position it at the forefront of this crucial evolution in personalized health technology.